VBI Vaccines selects two COVID-19 vaccine candidates for human trials


Aug 26 (Reuters) - VBI Vaccines Inc VBIV.O said on Wednesday it expected to begin human testing of two of its experimental COVID-19 vaccine candidates at the end of the year.

The two candidates, VBI-2901 and VBI-2902, were selected after three pre-clinical mouse studies induced neutralizing antibodies after a single dose, the company said.

The activity was analyzed using a plaque reduction neutralization test, considered the gold standard for measuring antibodies that can neutralize a virus, the company said.

VBI said its manufacturing partner, Therapure Biomanufacturing, will begin making bulk vaccines in September for use through mid-stage trials.

VBI, which was this month awarded C$56 million ($42 million) by the Canadian government to accelerate its COVID-19 vaccine development program, is one of the many companies racing to produce a safe and effective vaccine against the virus.

Many vaccine candidates are already in later stage of development.

Shares of the company rose 3.8% before the bell.

($1 = 1.32 Canadian dollars)

(Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila)

((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3463;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.